Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
22 hedge funds and large institutions have $6.7M invested in Bellicum Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 7 closing their positions.
13% less capital invested
Capital invested by funds: $7.68M → $6.7M (-$987K)
19% less funds holding
Funds holding: 27 → 22 (-5)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$280K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$74.1K |
| 3 |
Morgan Stanley
New York
|
+$14.5K |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$11.8K |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$813 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$173K |
| 2 |
XSC
X-Square Capital
Guaynabo,
Puerto Rico
|
-$166K |
| 3 |
SCM
Sio Capital Management
New York
|
-$58K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$52K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$203 | -30 | -54% |
|
BLCM Hedge Fund Activity: Q3 2020 in Review
22 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2020, worth a combined $6.7M — down 13% from $7.68M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BLCM and 2 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Qube Research & Technologies (QRT), opening a new position worth an estimated $280K. The largest seller was Renaissance Technologies, cutting an estimated $173K.
- 22 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2020, down from 27 in Q2 2020.
- Funds reported $6.7M of Bellicum Pharmaceuticals, Inc. stock for Q3 2020, down 13% quarter-over-quarter.
- 2 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2020 and 7 closed out, a net change of -5 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2020 was Qube Research & Technologies (QRT), an estimated $280K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2020 was Renaissance Technologies, an estimated $173K sold.
Based on aggregated 13F filings for Q3 2020.